You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海思科(002653.SZ):簽署一種長效治療骨關節炎的候選首創新藥Lorecivivint合作協議
格隆匯 09-14 14:58

格隆匯9月14日丨海思科(002653.SZ)公佈,公司與美國Biosplice Therapeutics,Inc. (“Biosplice”)簽署了一種長效治療骨關節炎的候選首創新藥 Lorecivivint  (Lorecivivint”)的《License Agreement》(“合作協議”)。海思科獲得獨家負責 Lorecivivint 在中國的開發、註冊和商業化活動的權益。

交易條款總價值最高1.4億美元,包括2000萬美金的首付款和註冊里程碑,以及一定的商業里程碑加上未來銷售的特許權使用費。

Lorecivivint 是一種 Biosplice 公司正在開發的擬應用於改善骨關節炎的藥物,並有可能成為近年來首個獲批用於骨關節功能改善的新機制創新藥。它是一種調節Wnt 通路CLK/DYRK 激酶抑制劑,目前正在美國進行治療膝骨關節炎的III 期臨牀試驗。在臨牀II 期試驗中,Lorecivivint 已顯示出與疼痛和骨關節功能相關的顯著療效和長期改善潛力。通過X 射線測量分析目標膝關節進行單次注射後52 周的內側關節間隙寬度,Lorecivivint 展示了其在骨關節結構上改善的益處。迄今為止,Lorecivivint 在研究中被證明是安全且耐受性良好的。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account